164 related articles for article (PubMed ID: 22214624)
1. Clinical characteristics and risk factors for mortality in patients with bacteremia caused by Pseudomonas aeruginosa.
Horino T; Chiba A; Kawano S; Kato T; Sato F; Maruyama Y; Nakazawa Y; Yoshikawa K; Yoshida M; Hori S
Intern Med; 2012; 51(1):59-64. PubMed ID: 22214624
[TBL] [Abstract][Full Text] [Related]
2. Pseudomonas aeruginosa bacteremia: resistance to antibiotics, risk factors, and patient mortality.
Vitkauskienė A; Skrodenienė E; Dambrauskienė A; Macas A; Sakalauskas R
Medicina (Kaunas); 2010; 46(7):490-5. PubMed ID: 20966623
[TBL] [Abstract][Full Text] [Related]
3. Clinical characteristics and outcomes of Pseudomonas aeruginosa bacteremia in febrile neutropenic children and adolescents with the impact of antibiotic resistance: a retrospective study.
Kim HS; Park BK; Kim SK; Han SB; Lee JW; Lee DG; Chung NG; Cho B; Jeong DC; Kang JH
BMC Infect Dis; 2017 Jul; 17(1):500. PubMed ID: 28716109
[TBL] [Abstract][Full Text] [Related]
4. Risk factors and outcome of Pseudomonas aeruginosa bacteremia among adults visiting the ED.
Lee CC; Lee CH; Hong MY
Am J Emerg Med; 2012 Jul; 30(6):852-60. PubMed ID: 21855263
[TBL] [Abstract][Full Text] [Related]
5. Impact of inappropriate empiric antimicrobial therapy on outcome in Pseudomonas aeruginosa bacteraemia: a stratified analysis according to sites of infection.
Joo EJ; Kang CI; Ha YE; Park SY; Kang SJ; Wi YM; Lee NY; Chung DR; Peck KR; Song JH
Infection; 2011 Aug; 39(4):309-18. PubMed ID: 21594653
[TBL] [Abstract][Full Text] [Related]
6. Risk factors and clinical significance of bacteremia caused by Pseudomonas aeruginosa resistant only to carbapenems.
Lee CH; Su TY; Ye JJ; Hsu PC; Kuo AJ; Chia JH; Lee MH
J Microbiol Immunol Infect; 2017 Oct; 50(5):677-683. PubMed ID: 26188977
[TBL] [Abstract][Full Text] [Related]
7. Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia; retrospective study of impact of combination antimicrobial therapy.
Kim YJ; Jun YH; Kim YR; Park KG; Park YJ; Kang JY; Kim SI
BMC Infect Dis; 2014 Mar; 14():161. PubMed ID: 24655422
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of appropriate empiric combination versus monotherapy for Pseudomonas aeruginosa bacteremia.
Bowers DR; Liew YX; Lye DC; Kwa AL; Hsu LY; Tam VH
Antimicrob Agents Chemother; 2013 Mar; 57(3):1270-4. PubMed ID: 23263001
[TBL] [Abstract][Full Text] [Related]
9. Risk factors for antimicrobial resistance and influence of resistance on mortality in patients with bloodstream infection caused by Pseudomonas aeruginosa.
Kang CI; Kim SH; Park WB; Lee KD; Kim HB; Kim EC; Oh MD; Choe KW
Microb Drug Resist; 2005; 11(1):68-74. PubMed ID: 15770098
[TBL] [Abstract][Full Text] [Related]
10. Risk factors for pan-resistant Pseudomonas aeruginosa bacteremia and the adequacy of antibiotic therapy.
Tuon FF; Gortz LW; Rocha JL
Braz J Infect Dis; 2012; 16(4):351-6. PubMed ID: 22846123
[TBL] [Abstract][Full Text] [Related]
11. Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome.
Kang CI; Kim SH; Kim HB; Park SW; Choe YJ; Oh MD; Kim EC; Choe KW
Clin Infect Dis; 2003 Sep; 37(6):745-51. PubMed ID: 12955633
[TBL] [Abstract][Full Text] [Related]
12. Inappropriate initial antimicrobial therapy as a risk factor for mortality in patients with community-onset Pseudomonas aeruginosa bacteraemia.
Cheong HS; Kang CI; Wi YM; Ko KS; Chung DR; Lee NY; Song JH; Peck KR
Eur J Clin Microbiol Infect Dis; 2008 Dec; 27(12):1219-25. PubMed ID: 18575908
[TBL] [Abstract][Full Text] [Related]
13. Pseudomonas aeruginosa bloodstream infections in children: a 9-year retrospective study.
Pilmis B; Alby-Laurent F; Fasola ML; Seegers V; Guery R; Guet-Revillet H; Postaire M; Toubiana J; Bille E; Lortholary O; Zahar JR
Eur J Pediatr; 2020 Aug; 179(8):1247-1254. PubMed ID: 32080759
[TBL] [Abstract][Full Text] [Related]
14. Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment.
Micek ST; Lloyd AE; Ritchie DJ; Reichley RM; Fraser VJ; Kollef MH
Antimicrob Agents Chemother; 2005 Apr; 49(4):1306-11. PubMed ID: 15793102
[TBL] [Abstract][Full Text] [Related]
15. [Effect of adequate initial antimicrobial therapy on mortality in critical patients with Pseudomonas aeruginosa bacteremia].
González AL; Leal AL; Cortés JA; Sánchez R; Barrero LI; Castillo JS; Álvarez CA
Biomedica; 2014 Apr; 34 Suppl 1():58-66. PubMed ID: 24968037
[TBL] [Abstract][Full Text] [Related]
16. Pseudomonas aeruginosa bacteremia upon hospital admission: risk factors for mortality and influence of inadequate empirical antimicrobial therapy.
Schechner V; Gottesman T; Schwartz O; Korem M; Maor Y; Rahav G; Karplus R; Lazarovitch T; Braun E; Finkelstein R; Lachish T; Wiener-Well Y; Alon D; Chowers M; Bardenstein R; Zimhony O; Paz A; Potasman I; Giladi M; Schwaber MJ; Klarfeld-Lidji S; Hochman M; Marchaim D; Carmeli Y
Diagn Microbiol Infect Dis; 2011 Sep; 71(1):38-45. PubMed ID: 21763093
[TBL] [Abstract][Full Text] [Related]
17. Bacteremia complicating urinary tract infection by Pseudomonas aeruginosa: Mortality risk factors.
Kitagawa K; Shigemura K; Yamamichi F; Osawa K; Uda A; Koike C; Tokimatsu I; Shirakawa T; Miyara T; Fujisawa M
Int J Urol; 2019 Mar; 26(3):358-362. PubMed ID: 30575137
[TBL] [Abstract][Full Text] [Related]
18. Clinical characteristics and risk factors for mortality in cefepime-resistant Pseudomonas aeruginosa bacteremia.
Su TY; Ye JJ; Hsu PC; Wu HF; Chia JH; Lee MH
J Microbiol Immunol Infect; 2015 Apr; 48(2):175-82. PubMed ID: 24064286
[TBL] [Abstract][Full Text] [Related]
19. Pseudomonas aeruginosa Bacteremia among Immunocompetent and Immunocompromised Patients: Relation to Initial Antibiotic Therapy and Survival.
Migiyama Y; Yanagihara K; Kaku N; Harada Y; Yamada K; Nagaoka K; Morinaga Y; Akamatsu N; Matsuda J; Izumikawa K; Kohrogi H; Kohno S
Jpn J Infect Dis; 2016; 69(2):91-6. PubMed ID: 26073727
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint.
Tam VH; Gamez EA; Weston JS; Gerard LN; Larocco MT; Caeiro JP; Gentry LO; Garey KW
Clin Infect Dis; 2008 Mar; 46(6):862-7. PubMed ID: 18279040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
